A qualitative rapid membrane immunochromatographic assay for the detection of Treponema pallidum (syphilis) antibodies in human whole blood (capillary). This test is intended for over-the-counter (OTC) at-home consumer use in individuals suspected of syphilis. The FDA-cleared First To Know^® rapid syphilis test provides clinicians with prompt actionable results, enabling for the faster identification of infected patients while at the point of care; also offers the opportunity for patients and their respective partners to self-test in the privacy of their home. Positive test results with the First To Know Syphilis Test alone are not sufficient to diagnose syphilis infection and must be followed by additional laboratory testing through a health care provider to confirm a diagnosis of syphilis.